Tung Sheng-Ling, Chou Ting-Ywan, Tseng Hung-Shi, Lee Chi-Ming
Department of Diagnostic Radiology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Department of Diagnostic Radiology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Taiwan J Obstet Gynecol. 2016 Oct;55(5):646-649. doi: 10.1016/j.tjog.2015.03.011.
To report our experiences with 40 patients who were treated with magnetic resonance-guided focused ultrasound surgery (MRgFUS) for uterine fibroids and their 6-month follow-up status.
A total of 40 patients with uterine fibroids underwent MRgFUS from January 2009 to November 2011. The Uterine Fibroid Symptoms and Quality of Life Questionnaire was used to determine the patients' Symptom Severity Scores (SSS) prior to and 6 months after treatment. The nonperfused volume (NPV) values and NPV ratio were obtained immediately at the end of the treatment and at 6 months follow-up.
No procedure-related complications were noted throughout the 6-month follow-up period among the 40 patients who underwent MRgFUS for uterine fibroids. The mean reduction in SSS in our patients after 6 months was 43.7%, and the mean reduction of fibroid volume was 31.7%. In addition, the mean reduction of NPV and mean NPV ratio was 52.7% and 33.3%, respectively.
The results obtained from this study demonstrated that MRgFUS can be safely and effectively used to ablate uterine fibroids to produce a significant decrease in mean fibroid volume and improve SSS for up to 6 months after treatment.
报告40例接受磁共振引导聚焦超声手术(MRgFUS)治疗子宫肌瘤患者的治疗经验及其6个月随访情况。
2009年1月至2011年11月,共有40例子宫肌瘤患者接受了MRgFUS治疗。采用子宫肌瘤症状与生活质量问卷确定患者治疗前及治疗后6个月的症状严重程度评分(SSS)。在治疗结束时及6个月随访时立即获取无灌注体积(NPV)值和NPV比率。
40例接受MRgFUS治疗子宫肌瘤的患者在6个月随访期间均未出现与手术相关的并发症。我们的患者在6个月后SSS的平均降低率为43.7%,肌瘤体积的平均缩小率为31.7%。此外,NPV的平均降低率和平均NPV比率分别为52.7%和33.3%。
本研究结果表明,MRgFUS可安全有效地用于消融子宫肌瘤,使肌瘤平均体积显著减小,并在治疗后长达6个月内改善SSS。